文献速递胸部肿瘤放疗

立体定向体部放疗治疗伴胸壁侵犯的T3N0非小细胞肺癌

Treatment of T3N0 non-small cell lung cancer with chest wall invasion using stereotactic body radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2019-02-21

研究利用前瞻性登记数据库识别12例因胸壁侵犯(CWI)导致的T3N0非小细胞肺癌患者,均接受根治性立体定向体部放疗(SBRT),多数处方剂量为50 Gy分5次。中位随访8.9个月时,1年原发肿瘤控制率89%、局部区域控制率82%、生存率63%,无3级及以上毒性。

要点

  • 12例T3N0因胸壁侵犯的非小细胞肺癌患者接受根治性SBRT,多数为50 Gy分5次。
  • 中位随访8.9个月时1年原发肿瘤控制率89%、局部区域控制率82%、生存率63%。
  • 4例治疗前胸壁疼痛患者中3例报告SBRT后改善,无3级及以上毒性。

核心结论

  • SBRT治疗因胸壁侵犯导致的T3N0非小细胞肺癌是安全的,具有较高的早期肿瘤控制率和较低的治疗相关毒性。
  • 大多数治疗前有胸壁疼痛的患者在SBRT后疼痛缓解,未观察到3级及以上毒性。

研究设计与样本

  • 利用前瞻性登记数据库识别2006年至2017年间治疗的12例因胸壁侵犯导致的T3N0非小细胞肺癌患者。
  • 胸壁侵犯定义为影像学证据显示软组织侵犯或骨质破坏,排除复发或转移性疾病患者。
  • 所有患者接受根治性SBRT,多数患者处方剂量为50 Gy分5次,采用Kaplan-Meier分析估计生存结局。

主要发现

  • 患者中位年龄70岁(范围58-85),中位肿瘤直径3.0 cm(范围0.9-7.2),中位生存期12.0个月(范围2.4-63)。
  • 中位随访8.9个月(范围2.1-63)时,1年原发肿瘤控制率为89%,受累肺叶控制率为89%,局部区域控制率为82%,远处控制率为91%,生存率为63%。
  • 4例治疗前有胸壁疼痛的患者中3例报告SBRT后改善;2例报告新发1-2级胸壁疼痛。
  • 未报告3级及以上毒性,1例发生1级皮肤毒性,3例发生1-2级放射性肺炎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Chest wall invasion (CWI) is observed in 5% of localized non-small cell lung cancer (NSCLC). The role of stereotactic body radiotherapy (SBRT) in these patients is unknown. We investigate the safety and efficacy of SBRT in patients with T3N0 NSCLC due to CWI. METHODS: Patients with T3N0 NSCLC due to CWI were identified using a prospective registry. CWI was defined as radiographic evidence of soft tissue invasion or bony destruction. We excluded patients with recurrent or metastatic disease. All patients were treated with definitive SBRT. Prescribed dose was 50 Gy in 5 fractions for most patients. Kaplan-Meier analysis was used to estimate survival outcomes. RESULTS: We identified 12 patients treated between 2006 and 2017. Median age was 70 (range, 58-85). Median tumor diameter was 3.0 cm (range, 0.9-7.2). Median survival was 12.0 months (range, 2.4-63). At a median follow-up of 8.9 months (range, 2.1-63), 1-year primary tumor control was 89%, involved lobar control was 89%, local-regional control was 82%, distant control was 91%, and survival was 63%. Of the 4 patients with pre-treatment chest wall pain, 3 reported improvement after SBRT. Two patients reported new grade 1-2 chest wall pain. No grade 3+ toxicity was reported, with 1 patient experiencing grade 1 skin toxicity and 3 patients experiencing grade 1-2 radiation pneumonitis. CONCLUSIONS: SBRT for CWI NSCLC is safe, with high early tumor control and low treatment-related toxicity. Most patients with pre-treatment chest wall pain experienced relief after SBRT, with no grade 3+ toxicity observed.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kennedy WR, Gabani P, Nikitas J, et al. Treatment of T3N0 non-small cell lung cancer with chest wall invasion using stereotactic body radiotherapy. Clin Transl Radiat Oncol. 2019. PMID: 30859139. doi:10.1016/j.ctro.2019.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。